Doxazosin: adverse event reports filed with FDA

4,251

reports as suspect product

0% of all reports · about 190 a year

341

reports, 12 months to June 2026

423 in the 12 months before

95.4%

marked serious by the reporter

76.2% across the class

6.1%

record death among outcomes, as reported

260 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Doxazosin reports recording the termmedian drug in alpha-adrenergic blocker

1. Hypotensionlow blood pressure8.9%377
2. Dyspnoeashortness of breath8.3%353
3. Drug ineffectivethe medicine did not work as expected7.7%327
4. Dizzinesslight-headedness or unsteadiness7.2%306
5. Syncopefainting6.6%281
6. Headachehead pain5.8%245
7. Drug interactionan interaction between medicines5.7%243
8. Condition aggravatedthe condition being treated got worse5.7%241
9. Hypertensionhigh blood pressure5.2%221
10. Asthmaasthma5.1%218
11. Nauseafeeling sick4.4%186
12. Productive cougha cough with phlegm4.4%185
13. Wheezingwheezing4.2%178
14. Acute kidney injurysudden loss of kidney function4.1%174
15. Arteriosclerosis4%168
16. Fatiguetiredness3.8%163
17. Hypoxialow oxygen3.6%151
18. Pain in extremitypain in an arm or leg3.6%151
19. Orthostatic hypotension3.5%150
20. Loss of consciousnesspassing out3.5%147
21. Thrombosis3.5%147
22. Pulmonary embolisma blood clot in the lung3.3%142
23. Therapeutic product effect incomplete3.3%140
24. Obstructive airways disorder3.2%138
25. Diarrhoealoose or frequent stools3.2%134
26. Anxietyanxiety3.1%133
27. Conjunctivitis allergic3.1%133
28. Full blood count abnormal3.1%133
29. Falla fall3%129
30. Sleep disorder due to a general medical condition3%128

Top 30 of 932 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 12 drugs in the alpha-adrenergic blocker class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 38,454 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 14.7% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 4,251 reports.

Drugs most often listed in the same reports

Other products listed in reports where Doxazosin is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the alpha-adrenergic blocker class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Doxazosin as a suspect or interacting product; reports listing it only as a concomitant medication (17,221) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.